Summary of the screening data for the in vitro antitumor activity of 1 and 2 (μM)a.
| Cell line | MCF-7 | HeLa | A-498 | MIA-PA-CA-2 | Hep-G2 | |
|---|---|---|---|---|---|---|
| GI50 | Complex 1 | <1 | <1 | <1 | 1.85 | <1 |
| Complex 2 | 1.826 | 3.204 | 3.21 | 3.172 | 4.406 | |
| ADR | <1 | <1 | <1 | <1 | <1 | |
| TGI | Complex 1 | 5.16 | 1.50 | 1.67 | 6.93 | 2.92 |
| Complex 2 | 4.80 | 5.35 | 5.46 | 5.57 | 6.26 | |
| ADR | 3.93 | <1 | <1 | <1 | <1 | |
| LC50 | Complex 1 | NE | 5.29 | 5.71 | NE | 5.94 |
| Complex 2 | 7.77 | 7.49 | 7.71 | 7.97 | >8 | |
| ADR | NE | NE | NE | NE | 4.19 |
a
GI50 = growth inhibition of 50% (GI50) calculated from [(Ti − Tz)/(C − Tz)] × 100 = 50, drug concentration that results in a 50% reduction in the net protein increase. ADR = adriamycin (positive control). GI50 value < 10 μg ml−1 is considered to demonstrate activity. TGI = tumor growth inhibition. LC50 = lethal concentration of 50% (LC50).